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Introducing new joint replacements to clinical practice
Requires collaboration between clinicians and regulators, together with comprehensive surveillance
data
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Total hip arthroplasty is one of the greatest success stories in
modern medicine. Since its inception in the late 1960s, millions
have benefited from its ability to relieve pain and improve
function, and it is now so successful that it is being used to treat
arthritis of the hip in younger patients. The two problems with
arthroplasty have always been fixation and wear. In the 1980s,
the problem of fixation of components to the skeleton was
overcome with both cemented and uncemented component
designs that were developed to give excellent and long lasting
fixation. Modifications of bearing surfaces and implant design
have been introduced in an attempt to improve function, wear
resistance, and implant survival. The recently published
systematic review by Sedrakyan and colleagues used data from
clinical trials, observational studies, and arthroplasty registries
to compare traditional metal on polyethylene bearings with
newer ceramic on ceramic and metal on metal bearings.1 The
last two “hard on hard” bearings were thought to be advances
that would reduce wear and facilitate hip resurfacing and the
use of larger diameter femoral head sizes, which confer
increased stability in arthroplasty.2 3 The review shows that the
perceived advantages are not being reflected in outcomes in
arthroplasty registries.1 Some metal bearing hips have been
associated with high complication rates.
All innovation carries risk, but without innovation patient care
will not be improved. An efficient and timely process is needed
to minimise the risks but also support the process of innovation,
rather than restrict or delay it. Currently, there is a mismatch
between the evidence from joint registries and the trends in joint
replacement: cemented cups need to be revised least often in
the first five years but their use is declining. This implies that
surgeons see sources of data other than registers as important.
Joint registries allow the creation of large datasets in an area in
which many small, albeit controlled, studies have been
published. Controlled studies have limitations—for example,
can all surgeons perform all implant types equally well?
However, registries also have limitations, such as the quality
and completeness of data entry. In addition, they tend to focus
on failure (revision or redo surgery) as the only outcome
measure, with little regard for function.4 The Birmingham hip
resurfacing arthroplasty study has shown excellent results at 10
years in the most challenging patient group for arthroplasty
surgeons—namely, active men under 55 years of age who have
large hips and normal or impingement anatomy.5However, this
apparent advantage was not evident from the data captured by
joint registries in the first five years, possibly because it is a
technically difficult operation andmany surgeons may be using
the device for different indications with less certain results.
The introduction of new artificial hip implants is an important
multidisciplinary field with close relationships between industry,
non-clinical and clinical scientists, healthcare regulators, and
surgeons. The systems to manage the introduction of new
implants should ideally apply robust scientific evidence in a
standardised manner that still encourages innovation. However,
the higher rates of failure and unexpected mechanisms of failure
seen with metal on metal hip implants have stimulated a review
of the system of medical device regulation by the United States
Food and Drug Administration.6 Of particular concern is the
fast track route, whereby a device is claimed to have equivalent
safety and efficacy to those devices already in use—the “me
too group” approved by premarket notification under the 510(k)
clearance. Small changes to prosthesis design often have big
effects on clinical outcomes.7 In Europe, the CE (European
conformity) marking system is also open to less rigorous
scrutiny: approval by one of the many official CE awarding
bodies enables pan-European use of a new device. There is no
facility to release a radically new design for clinical testing in
small groups of tightly controlled and studied patients in specific
centres. If a CE mark is granted, the device can be implanted
Europe wide.
The United Kingdom is uniquely positioned to evaluate new
technology because it has the largest national arthroplasty
register in the world, a national patient reported outcome
measures project covering hip and knee replacement, and an
orthopaedic devices evaluation project (ODEP) review process
that assesses the published data (ODEP considers data from all
published sources, including industry) and national and
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international arthroplasty data on hip prostheses and bench
marks these against accepted standards. These standards are the
National Institute for Health and Clinical Excellence guidelines
that an implant should have, or be compatible with, 90% success
at 10 years, or if before 10 years, have a failure rate of not more
than 1% per year. What is missing is a process that brings these
data together in a timely fashion to identify both good and poor
performance as quickly as possible. This would enable
successful technology to be introduced quickly and safely but
poor technology to be identified earlier and, if necessary,
stopped to reduce the risk to patients. It is in no one’s interest
to implant poorly performing implants.
Collaboration between interested parties delivers results. The
UK was the first country to introduce guidance on metal on
metal joint replacement after collaboration between the British
Orthopaedic Association, the British Hip Society, theMedicines
and Healthcare Products Regulatory Agency (MHRA), and the
National Joint Registry.8
This collaborative approach needs to be extended beyond
compliance with basic European Union rules that allow new
implants to be introduced. In this endeavour, the British
Orthopaedic Association has brought all stakeholders together
and recently led a meeting with the MHRA and industry to
establish how to improve the process by reviewing premarket
testing and clinical trials, as well as by greatly enhancing
post-market surveillance.9Better andmore effective post-market
surveillance is essential; arthroplasty registers have an important
role to play in this but may not be enough on their own.
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